A Case for Rejecting Pfizer's Bid for AstraZeneca BILL GEORGE AstraZeneca’s board would do well to evaluate whether the company’s progress will continue under Pfizer’s management, Bill George, a professor of management practice at Harvard Business School, writes in the Another View column. May 8, 2014 at 4:00AM http://nyti.ms/1qjpNmm http://nyti.ms/1j7wVbF The New York Times Business Day Drugs (Pharmaceuticals), Mergers, Acquisitions and Divestitures, Research, Taxation

By BILL GEORGE via NYT / Eethg. Corps. Inc. / Terrence Herschel G. Business Day http://nyti.ms/1qjpNmm A Case for Rejecting Pfizer's Bid for AstraZeneca May 8, 2014 at 4:00AM http://nyti.ms/1j7wVbF The New York Times